Skip to main content
SCYX
NASDAQ Life Sciences

SCYNEXIS Begins Phase 1 Trial for SCY-770, a Novel ADPKD Therapy

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.9
Mkt Cap
$38.43M
52W Low
$3.68
52W High
$10.48
52W Position info
6.0% above low
Off High info
63% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

SCYX is trading near its 52-week low of $3.68 (6.0% above the low) on light trading volume (0.4× avg).

Summary

SCYNEXIS has initiated a Phase 1 clinical study for SCY-770, a novel AMPK activator, targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). This marks a key development for the company's pipeline, following its recent acquisition of SCY-770 and a period of financial restructuring including a reverse stock split. Advancing this drug, which has Orphan Drug Designation and prior safety data, is crucial for a small biotech focused on rare diseases. Topline data from this Phase 1 study are expected in Q3 2026, with Phase 2 initiation planned for Q4 2026.

At the time of this announcement, SCYX was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.4M. The 52-week trading range was $3.68 to $10.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SCYX - Latest Insights

SCYX
Nov 05, 2026, 8:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $3.21 info
Change: -$0.630 (-16%) info
Market Cap: $31.95M info
SCYX
Oct 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.18
Real-time Price: $3.21 info
Change: -$1.97 (-38%) info
Market Cap: $31.95M info
SCYX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $3.21 info
Change: -$1.50 (-32%) info
Market Cap: $31.95M info
SCYX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $3.21 info
Change: -$3.25 (-50%) info
Market Cap: $31.95M info
SCYX
Aug 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $3.21 info
Change: -$2.06 (-39%) info
Market Cap: $31.95M info